The clinical information you need, at your fingertips.

Updated shots were associated with markedly lower odds of COVID admission and death, yet just 10% of this high-risk group had received them. . .

Real-world comparison helps inform initial treatment discussions for patients newly diagnosed with MS. . .

Infected individuals showed a 1.59-fold higher risk of the disease, and treating the infection was associated with lower long-term risk. . .

Phase 3 trials suggest IL-33 blockade may reduce exacerbations across a broad COPD population, regardless of eosinophil count. . .

Large registry study identifies the first 3 months after diagnosis as a high-risk period, especially for pancreatic and lung cancers. . .

RNA-targeting treatment missed its primary endpoint, but secondary signals may support further development. . .